Transplant

• 

  All Medical News

  BTS 2016: An interview with Dr Jayme Locke, Transplant Surgery, University of Alabama, Birmingham, AL, USA. The new US kidney allocation scheme.

  Written by Lorraine Carolan | 16 Mar 2016

• 

  All Medical News

  BTS 2016: Best practice immunosuppression – no more Mr Nice Guy. Interview with Lorna Marson, Lisa Burnapp and Professor Derek Manas from the BTS executive discuss the potential impact on patients if the appeal fails and Professor Nigel Heaton and Dr Varuna Aluvihare (Kings College Hospital) give a surgeon and hepatologist’s view on how NICE renal guidance might affect liver transplantation.

  Written by Lorraine Carolan | 15 Mar 2016

  Best practice immunosuppression – no more Mr Nice Guy.   Nicholas Torpey, Addenbrooke’s Hospital, Cambridge. Overview by Maria Dalby The updated recommendations from the National Institute for Health… read more.

• 

  All Medical News

  BTS 2016: Best practice immunosuppression – no more Mr Nice Guy. Interview with Lorna Marson, Lisa Burnapp and Professor Derek Manas from the BTS executive discuss the potential impact on patients if the appeal fails and Professor Nigel Heaton and Dr Varuna Aluvihare (Kings College Hospital) give a surgeon and hepatologist's view on how NICE renal guidance might affect liver transplantation.

  Written by Lorraine Carolan | 15 Mar 2016

  Best practice immunosuppression – no more Mr Nice Guy.   Nicholas Torpey, Addenbrooke’s Hospital, Cambridge. Overview by Maria Dalby The updated recommendations from the National Institute for Health… read more.

• 

  All Medical News

  BTS 2016: Lorna Marson and Professor John O’Grady discuss proposals for changes to the current kidney and liver allocation schemes in the UK.

  Written by Lorraine Carolan | 14 Mar 2016

  Organ Allocation: looking to the future.  An interview with Lorna Marson (University of Edinburgh) and Professor John O’Grady (Kings College Hospital, London)

• 

  All Medical News

  BTS 2016 Congress Highlights: Video Interview with Lorna Marson (Edinburgh), Professor Nigel Heaton (London), Lisa Burnapp (London), Jayme Locke (Birmingham, AL, USA), Dr Varuna Aluvihare (London), BTS President Professor Derek Manas (Newcastle) and Professor John O’Grady (London).

  Written by Lorraine Carolan | 11 Mar 2016

  The BTS Executive and delegates share their highlights of the British Transplantation Society Annual Congress held from 24th-26th February 2016, Glasgow SECC.

• 

  All Medical News

  World Health Matters: Italy: Leukaemia death rate expected to fall in 2016

  Written by Gary Finnegan | 22 Feb 2016

  by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.

• 

  All Medical News

  ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

  Written by Lorraine Carolan | 5 Feb 2016

• 

  All Medical News

  ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

  Written by Lorraine Carolan | 21 Jan 2016

  Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

• 

  All Medical News

  ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

  Written by Lorraine Carolan | 18 Jan 2016

  by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

• 

  All Medical News

  ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

  Written by Lorraine Carolan | 13 Jan 2016

  by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.

• 

  All Medical News

  ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

  Written by Lorraine Carolan | 30 Dec 2015

  by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

• 

  All Medical News

  ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

  Written by Lorraine Carolan | 29 Dec 2015

  by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.